BACKGROUND: We investigated the safety and efficacy of the addition of a trust index to enhanced Model Predictive Control (eMPC) Artificial Pancreas (AP) that works by adjusting the responsiveness of the controller's insulin delivery based on the confidence intervals around predictions of glucose trends. This constitutes a dynamic adaptation of the controller's parameters in contrast with the widespread AP implementation of individualized fixed controller tuning. MATERIALS AND METHODS: After 1 week of sensor-augmented pump (SAP) use, subjects completed a 48-h AP admission that included three meals/day (carbohydrate range 29-57 g/meal), a 1-h unannounced brisk walk, and two overnight periods. Endpoints included sensor glucose percentage time 70-180, <70, >180 mg/dL, number of hypoglycemic events, and assessment of the trust index versus standard eMPC glucose predictions. RESULTS: Baseline characteristics for the 15 subjects who completed the study (mean ± SD) were age 46.1 ± 17.8 years, HbA1c 7.2% ± 1.0%, diabetes duration 26.8 ± 17.6 years, and total daily dose (TDD) 35.5 ± 16.4 U/day. Mean sensor glucose percent time 70-180 mg/dL (88.0% ± 8.0% vs. 74.6% ± 9.4%), <70 mg/dL (1.5% ± 1.9% vs. 7.8% ± 6.0%), and number of hypoglycemic events (0.6 ± 0.6 vs. 6.3 ± 3.4), all showed statistically significant improvement during AP use compared with the SAP run-in (P < 0.001). On average, the trust index enhanced controller responsiveness to predicted hyper- and hypoglycemia by 26% (P < 0.005). CONCLUSIONS: In this population of well-controlled patients, we conclude that eMPC with trust index AP achieved nearly 90% time in the target glucose range. Additional studies will further validate these results.
BACKGROUND: We investigated the safety and efficacy of the addition of a trust index to enhanced Model Predictive Control (eMPC) Artificial Pancreas (AP) that works by adjusting the responsiveness of the controller's insulin delivery based on the confidence intervals around predictions of glucose trends. This constitutes a dynamic adaptation of the controller's parameters in contrast with the widespread AP implementation of individualized fixed controller tuning. MATERIALS AND METHODS: After 1 week of sensor-augmented pump (SAP) use, subjects completed a 48-h AP admission that included three meals/day (carbohydrate range 29-57 g/meal), a 1-h unannounced brisk walk, and two overnight periods. Endpoints included sensor glucose percentage time 70-180, <70, >180 mg/dL, number of hypoglycemic events, and assessment of the trust index versus standard eMPC glucose predictions. RESULTS: Baseline characteristics for the 15 subjects who completed the study (mean ± SD) were age 46.1 ± 17.8 years, HbA1c 7.2% ± 1.0%, diabetes duration 26.8 ± 17.6 years, and total daily dose (TDD) 35.5 ± 16.4 U/day. Mean sensor glucose percent time 70-180 mg/dL (88.0% ± 8.0% vs. 74.6% ± 9.4%), <70 mg/dL (1.5% ± 1.9% vs. 7.8% ± 6.0%), and number of hypoglycemic events (0.6 ± 0.6 vs. 6.3 ± 3.4), all showed statistically significant improvement during AP use compared with the SAP run-in (P < 0.001). On average, the trust index enhanced controller responsiveness to predicted hyper- and hypoglycemia by 26% (P < 0.005). CONCLUSIONS: In this population of well-controlled patients, we conclude that eMPC with trust index AP achieved nearly 90% time in the target glucose range. Additional studies will further validate these results.
Authors: Jordan E Pinsker; Joon Bok Lee; Eyal Dassau; Dale E Seborg; Paige K Bradley; Ravi Gondhalekar; Wendy C Bevier; Lauren Huyett; Howard C Zisser; Francis J Doyle Journal: Diabetes Care Date: 2016-06-11 Impact factor: 19.112
Authors: Joon Bok Lee; Eyal Dassau; Ravi Gondhalekar; Dale E Seborg; Jordan E Pinsker; Francis J Doyle Journal: Ind Eng Chem Res Date: 2016-10-27 Impact factor: 3.720
Authors: Stacey M Anderson; Dan Raghinaru; Jordan E Pinsker; Federico Boscari; Eric Renard; Bruce A Buckingham; Revital Nimri; Francis J Doyle; Sue A Brown; Patrick Keith-Hynes; Marc D Breton; Daniel Chernavvsky; Wendy C Bevier; Paige K Bradley; Daniela Bruttomesso; Simone Del Favero; Roberta Calore; Claudio Cobelli; Angelo Avogaro; Anne Farret; Jerome Place; Trang T Ly; Satya Shanmugham; Moshe Phillip; Eyal Dassau; Isuru S Dasanayake; Craig Kollman; John W Lum; Roy W Beck; Boris Kovatchev Journal: Diabetes Care Date: 2016-04-13 Impact factor: 19.112
Authors: Rebecca A Harvey; Eyal Dassau; Wendy C Bevier; Dale E Seborg; Lois Jovanovič; Francis J Doyle; Howard C Zisser Journal: Diabetes Technol Ther Date: 2014-01-28 Impact factor: 6.118
Authors: H Thabit; M Tauschmann; J M Allen; L Leelarathna; S Hartnell; M E Wilinska; C L Acerini; S Dellweg; C Benesch; L Heinemann; J K Mader; M Holzer; H Kojzar; J Exall; J Yong; J Pichierri; K D Barnard; C Kollman; P Cheng; P C Hindmarsh; F M Campbell; S Arnolds; T R Pieber; M L Evans; D B Dunger; R Hovorka Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Satish K Garg; Stuart A Weinzimer; William V Tamborlane; Bruce A Buckingham; Bruce W Bode; Timothy S Bailey; Ronald L Brazg; Jacob Ilany; Robert H Slover; Stacey M Anderson; Richard M Bergenstal; Benyamin Grosman; Anirban Roy; Toni L Cordero; John Shin; Scott W Lee; Francine R Kaufman Journal: Diabetes Technol Ther Date: 2017-01-30 Impact factor: 6.118
Authors: Bruce A Buckingham; Gregory P Forlenza; Jordan E Pinsker; Mark P Christiansen; R Paul Wadwa; Jennifer Schneider; Thomas A Peyser; Eyal Dassau; Joon Bok Lee; Jason O'Connor; Jennifer E Layne; Trang T Ly Journal: Diabetes Technol Ther Date: 2018-02-12 Impact factor: 6.118
Authors: D Elleri; M Biagioni; J M Allen; K Kumareswaran; L Leelarathna; K Caldwell; M Nodale; M E Wilinska; A Haidar; P Calhoun; C Kollman; N C Jackson; A M Umpleby; C L Acerini; D B Dunger; R Hovorka Journal: Diabetes Obes Metab Date: 2015-10-09 Impact factor: 6.577
Authors: John H Abel; Marcus A Badgeley; Taylor E Baum; Sourish Chakravarty; Patrick L Purdon; Emery N Brown Journal: Proc IFAC World Congress Date: 2021-04-14
Authors: Christopher M Mulla; Stamatina Zavitsanou; Alejandro Jose Laguna Sanz; David Pober; Lauren Richardson; Pamela Walcott; Ipsa Arora; Brett Newswanger; Martin J Cummins; Steve J Prestrelski; Francis J Doyle; Eyal Dassau; Mary Elizabeth Patti Journal: J Clin Endocrinol Metab Date: 2020-04-01 Impact factor: 5.958